

Specimen Collected: 05-Sep-23 12:42

Targeted drug prof, Mass Spec/EMIT, UR	Received: 05-Sep-23 12:42	Report/Verified: 05-Sep-23 12:59
---	----------------------------------	---

Procedure	Result	Units	Reference Interval
Creatinine,Urine	100.0	mg/dL	[20.0-400.0]

Targeted drug prof, Mass Spec/EMIT, UR	Received: 05-Sep-23 12:42	Report/Verified: 05-Sep-23 13:00
---	----------------------------------	---

Procedure	Result	Units	Reference Interval
Targeted Drug Profile Comment	See Note ⁱ¹		
EER Targeted Drug Profile,U	See Note ^{f1}		
Barbiturates Screen,U	PresumptivePOS ^{f2 i2}		
Carisoprodol Screen,U	PresumptivePOS ^{f2 i3}		
THC (Cannabinoids) Screen,U	PresumptivePOS ^{f2 i4}		
Cocaine Screen,U	PresumptivePOS ^{f2 i5}		
Ethyl Glucuronide Screen,U	PresumptivePOS ^{f2 i6}		
Methadone Screen,U	PresumptivePOS ^{f2 i7}		
Phencyclidine Screen,U	PresumptivePOS ^{f2 i8}		
Tramadol Screen,U	PresumptivePOS ^{f2 i9}		

Targeted drug prof, Mass Spec/EMIT, UR	Received: 05-Sep-23 12:42	Report/Verified: 05-Sep-23 13:07
---	----------------------------------	---

Procedure	Result	Units	Reference Interval
6-acetylmorphine,U	Not Detected ⁱ¹⁰		
7-Aminoclonazepam,U	Not Detected ⁱ¹¹		
Alpha-OH-Alprazolam,U	Not Detected ⁱ¹²		
Alpha-OH-Midazolam,U	Not Detected ⁱ¹³		
Alprazolam,U	Not Detected ⁱ¹⁴		
Amphetamine,U	Not Detected ⁱ¹⁵		
Buprenorphine,U	Not Detected ⁱ¹⁶		
Clonazepam,U	Not Detected ⁱ¹⁷		
Codeine,U	Not Detected ⁱ¹⁸		
Diazepam,U	Not Detected ⁱ¹⁹		
Fentanyl,U	Not Detected ⁱ²⁰		
Gabapentin,U	Not Detected ⁱ²¹		
Hydrocodone,U	Not Detected ⁱ²²		
Hydromorphone,U	Not Detected ⁱ²³		
Lorazepam,U	Not Detected ⁱ²⁴		
MDA,U	Not Detected ⁱ²⁵		
MDEA,U	Not Detected ⁱ²⁶		
MDMA,U	Not Detected ⁱ²⁷		
Meperidine metabolite,U	Not Detected ⁱ²⁸		
Methamphetamine,U	Not Detected ⁱ²⁹		
Methylphenidate,U	Not Detected ⁱ³⁰		
Midazolam,U	Not Detected ⁱ³¹		
Morphine,U	Not Detected ⁱ³²		

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-248-900127

Report Request ID: 18462397

Printed: 05-Sep-23 13:12

Page 1 of 8

Targeted drug prof, Mass Spec/EMIT, UR		Received: 05-Sep-23 12:42	Report/Verified: 05-Sep-23 13:07
Procedure	Result	Units	Reference Interval
Naloxone,U	Not Detected ⁱ³³		
Norbuprenorphine,U	Not Detected ⁱ³⁴		
Nordiazepam,U	Not Detected ⁱ³⁵		
Norfentanyl,U	Not Detected ⁱ³⁶		
Norhydrocodone,U	Not Detected ⁱ³⁷		
Noroxycodone,U	Not Detected ⁱ³⁸		
Noroxymorphone,U	Not Detected ⁱ³⁹		
Oxazepam,U	Not Detected ⁱ⁴⁰		
Oxycodone,U	Not Detected ⁱ⁴¹		
Oxymorphone,U	Not Detected ⁱ⁴²		
Phentermine,U	Not Detected ⁱ⁴³		
Pregabalin,U	Not Detected ⁱ⁴⁴		
Tapentadol,U	Not Detected ⁱ⁴⁵		
Tapentadol-o-Sulf,U	Not Detected ⁱ⁴⁶		
Temazepam,U	Not Detected ⁱ⁴⁷		
Zolpidem,U	Not Detected ⁱ⁴⁸		
Zolpidem Metabolite,U	Not Detected ⁱ⁴⁹		

Result Footnote

f1: EER Targeted Drug Profile, U
 Authorized individuals can access the ARUP
 Enhanced Report using the following link:

f2: Barbiturates Screen, U, Carisoprodol Screen, U, Cocaine Screen, U, Ethyl Glucuronide Screen, U, Methadone
 Screen, U, Phencyclidine Screen, U, THC (Cannabinoids) Screen, U, Tramadol Screen, U

Presumptive positive by immunoassay. Testing by mass spectrometry is available on request.

Test Information

i1: Targeted Drug Profile Comment
 Methodology: Qualitative Enzyme Immunoassay and Qualitative Liquid
 Chromatography-Tandem Mass Spectrometry, Quantitative Spectrophotometry

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration must be greater than or equal to the cutoff to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.

Results based on immunoassay detection that do not match clinical expectations should be

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-248-900127

Report Request ID: 18462397

Printed: 05-Sep-23 13:12

Page 2 of 8

Test Information

- i1: Targeted Drug Profile Comment
interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available, if ordered within two weeks of specimen collection. Additional charges apply.
- For medical purposes only; not valid for forensic use.
- This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
- i2: Barbiturates Screen, U
INTERPRETIVE INFORMATION: Barbiturates Screen, U
- Positive Cutoff: 200 ng/mL
Methodology: Immunoassay
- i3: Carisoprodol Screen, U
INTERPRETIVE INFORMATION: Carisoprodol Screen, U
- Positive Cutoff: 100 ng/mL
Methodology: Immunoassay
- i4: The carisoprodol immunoassay has cross-reactivity to carisoprodol and meprobamate.
THC (Cannabinoids) Screen, U
INTERPRETIVE INFORMATION: THC (Cannabinoids) Screen, U
- Positive Cutoff: 50 ng/mL
Methodology: Immunoassay
- i5: Cocaine Screen, U
INTERPRETIVE INFORMATION: Cocaine Screen, U
- Positive Cutoff: 150 ng/mL
Methodology: Immunoassay
- i6: Ethyl Glucuronide Screen, U
INTERPRETIVE INFORMATION: Ethyl Glucuronide Screen, U
- Positive Cutoff: 500 ng/mL
Methodology: Immunoassay
- i7: Methadone Screen, U
INTERPRETIVE INFORMATION: Methadone Screen, U
- Positive Cutoff: 150 ng/mL
Methodology: Immunoassay
- i8: Phencyclidine Screen, U
INTERPRETIVE INFORMATION: Phencyclidine Screen, U

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-248-900127

Report Request ID: 18462397

Printed: 05-Sep-23 13:12

Page 3 of 8

Test Information

i8: Phencyclidine Screen, U
Positive Cutoff: 25 ng/mL
Methodology: Immunoassay

i9: Tramadol Screen, U
INTERPRETIVE INFORMATION: Tramadol Screen, U

Positive Cutoff: 100 ng/mL
Methodology: Immunoassay

i10: 6-acetylmorphine, U
INTERPRETIVE INFORMATION: 6-acetylmorphine, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

i11: 7-Aminoclonazepam, U
INTERPRETIVE INFORMATION: 7-Aminoclonazepam, U

Positive Cutoff: 40 ng/mL
Methodology: Mass Spectrometry

i12: Alpha-OH-Alprazolam, U
INTERPRETIVE INFORMATION: Alpha-OH-Alprazolam, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

i13: Alpha-OH-Midazolam, U
INTERPRETIVE INFORMATION: Alpha-OH-Midazolam, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

i14: Alprazolam, U
INTERPRETIVE INFORMATION: Alprazolam, U

Positive Cutoff: 40 ng/mL
Methodology: Mass Spectrometry

i15: Amphetamine, U
INTERPRETIVE INFORMATION: Amphetamine, U

Positive Cutoff: 50 ng/mL
Methodology: Mass Spectrometry

i16: Buprenorphine, U
INTERPRETIVE INFORMATION: Buprenorphine, U

Positive Cutoff: 5 ng/mL
Methodology: Mass Spectrometry

i17: Clonazepam, U
INTERPRETIVE INFORMATION: Clonazepam, U

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-248-900127**Report Request ID:** 18462397**Printed:** 05-Sep-23 13:12

Page 4 of 8

Test Information

i17: Clonazepam, U
Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

i18: Codeine, U
INTERPRETIVE INFORMATION: Codeine, U

Positive Cutoff: 40 ng/mL
Methodology: Mass Spectrometry

i19: Diazepam, U
INTERPRETIVE INFORMATION: Diazepam, U

Positive Cutoff: 50 ng/mL
Methodology: Mass Spectrometry

i20: Fentanyl, U
INTERPRETIVE INFORMATION: Fentanyl, U

Positive Cutoff: 2 ng/mL
Methodology: Mass Spectrometry

i21: Gabapentin, U
INTERPRETIVE INFORMATION: Gabapentin, U

Positive Cutoff: 3,000 ng/mL
Methodology: Mass Spectrometry

i22: Hydrocodone, U
INTERPRETIVE INFORMATION: Hydrocodone, U

Positive Cutoff: 40 ng/mL
Methodology: Mass Spectrometry

i23: Hydromorphone, U
INTERPRETIVE INFORMATION: Hydromorphone, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

i24: Lorazepam, U
INTERPRETIVE INFORMATION: Lorazepam, U

Positive Cutoff: 60 ng/mL
Methodology: Mass Spectrometry

i25: MDA, U
INTERPRETIVE INFORMATION: MDA, U

Positive Cutoff: 200 ng/mL
Methodology: Mass Spectrometry

i26: MDEA, U
INTERPRETIVE INFORMATION: MDEA, U

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-248-900127**Report Request ID:** 18462397**Printed:** 05-Sep-23 13:12

Page 5 of 8

Test Information

i26: MDEA, U
Positive Cutoff: 200 ng/mL
Methodology: Mass Spectrometry

i27: MDMA, U
INTERPRETIVE INFORMATION:MDMA, U

Positive Cutoff: 200 ng/mL
Methodology: Mass Spectrometry

i28: Meperidine metabolite, U
INTERPRETIVE INFORMATION:Meperidine metabolite, U

Positive Cutoff: 50 ng/mL
Methodology: Mass Spectrometry

i29: Methamphetamine, U
INTERPRETIVE INFORMATION:Methamphetamine, U

Positive Cutoff: 200 ng/mL
Methodology: Mass Spectrometry

i30: Methylphenidate, U
INTERPRETIVE INFORMATION:Methylphenidate, U

Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

i31: Midazolam, U
INTERPRETIVE INFORMATION:Midazolam, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

i32: Morphine, U
INTERPRETIVE INFORMATION:Morphine, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

i33: Naloxone, U
INTERPRETIVE INFORMATION:Naloxone, U

Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

i34: Norbuprenorphine, U
INTERPRETIVE INFORMATION:Norbuprenorphine, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

i35: Nordiazepam, U
INTERPRETIVE INFORMATION:Nordiazepam, U

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-248-900127

Report Request ID: 18462397

Printed: 05-Sep-23 13:12

Page 6 of 8

Test Information

i35: Nordiazepam, U
Positive Cutoff: 50 ng/mL
Methodology: Mass Spectrometry

i36: Norfentanyl, U
INTERPRETIVE INFORMATION: Norfentanyl, U

Positive Cutoff: 2 ng/mL
Methodology: Mass Spectrometry

i37: Norhydrocodone, U
INTERPRETIVE INFORMATION: Norhydrocodone, U

Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

i38: Noroxycodone, U
INTERPRETIVE INFORMATION: Noroxycodone, U

Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

i39: Noroxymorphone, U
INTERPRETIVE INFORMATION: Noroxymorphone, U

Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

i40: Oxazepam, U
INTERPRETIVE INFORMATION: Oxazepam, U

Positive Cutoff: 50 ng/mL
Methodology: Mass Spectrometry

i41: Oxycodone, U
INTERPRETIVE INFORMATION: Oxycodone, U

Positive Cutoff: 40 ng/mL
Methodology: Mass Spectrometry

i42: Oxymorphone, U
INTERPRETIVE INFORMATION: Oxymorphone, U

Positive Cutoff: 40 ng/mL
Methodology: Mass Spectrometry

i43: Phentermine, U
INTERPRETIVE INFORMATION: Phentermine, U

Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

i44: Pregabalin, U
INTERPRETIVE INFORMATION: Pregabalin, U

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-248-900127

Report Request ID: 18462397

Printed: 05-Sep-23 13:12

Page 7 of 8

Patient Age/Sex: 26 years Female

Test Information

i44: Pregabalin, U
Positive Cutoff: 3,000 ng/mL
Methodology: Mass Spectrometry

i45: Tapentadol, U
INTERPRETIVE INFORMATION: Tapentadol, U

Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

i46: Tapentadol-o-Sulf, U
INTERPRETIVE INFORMATION: Tapentadol-o-Sulf, U

Positive Cutoff: 200 ng/mL
Methodology: Mass Spectrometry

i47: Temazepam, U
INTERPRETIVE INFORMATION: Temazepam, U

Positive Cutoff: 50 ng/mL
Methodology: Mass Spectrometry

i48: Zolpidem, U
INTERPRETIVE INFORMATION: Zolpidem, U

Positive Cutoff: 20 ng/mL
Methodology: Mass Spectrometry

i49: Zolpidem Metabolite, U
INTERPRETIVE INFORMATION: Zolpidem Metabolite, U

Positive Cutoff: 100 ng/mL
Methodology: Mass Spectrometry

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:**ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-248-900127**Report Request ID:** 18462397**Printed:** 05-Sep-23 13:12

Page 8 of 8